FDA Reversal on COVID-19 Mask Decontamination Follows MNA Opposition, Demonstrates Urgent Need for Implementation of Frontline Nurse and Healthcare Professional Guidance

June 8, 2020

FDA reversed its position on the use of N95 masks that have been decontaminated on Sunday, June 7, aligning with the Massachusetts Nurses Association’s longstanding opposition to these unproven and potentially dangerous practices.

The FDA wrote in a public statement on Sunday: “In response to public health and safety concerns about the appropriateness of decontaminating certain respirators, the agency is reissuing certain emergency use authorizations (EUAs) to specify which respirators are appropriate for decontamination. Based on the FDA’s increased understanding of the performance and design of these respirators, the FDA has decided that certain respirators should not be decontaminated for reuse by health care personnel.”

RN and MNA President Donna Kelly-Williams said in response to the FDA reversal: “Government officials and healthcare executives wasted time and resources and put frontline workers at risk chasing the unproven and dangerous dream of mask decontamination. Nurses and healthcare professionals caring for patients during this pandemic knew all along that these processes lacked rigorous evidence, could damage N95 masks and may create lasting health problems.

“The MNA spoke out strongly against decontamination early on, instead urging government and healthcare leaders to make sure every frontline healthcare worker had a new N95 mask to protect them against exposure and limit the spread of COVID-19,” Kelly-Williams said. “The FDA’s reversal on decontamination is a glaring example of why nurses and healthcare professionals on the frontlines must be heard.

“Prioritizing the opinions of healthcare executives and hospital lobbying groups over the guidance of those fighting in the trenches of this pandemic has placed nurses and patients in jeopardy,” Kelly-Williams said. “As healthcare facilities re-open additional services, it is absolutely essential – for the safety of caregivers, patients and the public – that the recommendations of those on the frontlines are heard and implemented.”

The MNA has taken a leadership position in opposing the use of these products due to the risks to the health and safety of nurses and other healthcare workers who are caring for patients. In a position statement released to the public on April 29, the MNA called for the halt of decontamination of masks, and that nurses and healthcare professionals have the right to consent or refuse to use decontaminated masks.

“The lack of reliable information on these practices, as well as the potential safety risks of these decontamination procedures, pose risks to the health and safety of health care workers, as well as the general public at large require that these practices be halted,” reads the MNA position statement.

The reversal of the FDAs position has resulted in the agency’s reissuing of the Emergency Use Authorizations (EUAs) for the following products:

“…decontaminated respirators should only be used when new FDA-cleared N95 respirators, NIOSH-approved N95 respirators, or other FDA authorized respirators are not available. The decontamination systems are only authorized to decontaminate non-cellulose compatible N95 respirators. As such, health care personnel should not reuse a respirator that is incompatible with an authorized decontamination system but has nonetheless been decontaminated. Users of any respirator (whether or not decontaminated) should always assess for proper fit after placement. Respirators with poor fit, visible soiling, or damage should not be used.”

These changes prohibit the decontamination of N95 respirators that were manufactured in China, which accounts for the majority of available products utilized across the globe. The MNA is calling on healthcare organizations to act immediately to procure an adequate supply of new personal protective products (PPE) that meet the standard that had been in place pre-pandemic.

The MNA also calls on the state to follow the FDA’s lead and prohibit all hospital systems for utilizing decontaminated masks, and for the federal government to fully activate the Defense Production Act to mobilize immediate production of safe and appropriate N95 masks to allow for the safe reopening of health care services, as well as to prepare for a potential second wave of COVID-19 exposure in the fall. If proactive steps are not taken to secure these products now, the risks to public health and worker safety may be irreparable.

More information and additional MNA COVID-19 recommendations can be found here.

Hot this week

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.